BMPR Specific Neutra™ Antibody Products

Bone morphogenetic protein receptors (BMPR) constitute a class of serine-threonine kinase receptors, encompassing transmembrane receptors crucial for tissue development and cellular signaling. Members of the TGF-β family bind to BMPRs. The four BMPRs include: Type 1 receptors, namely ACVR1, BMPR1A, and BMPR1B; and Type 2 receptors. BMPR1A and BMPR1B play essential roles in osteoblast differentiation and chondrogenesis, affecting bone remodeling. BMPR signaling contributes to embryonic patterning, cell migration, proliferation, and differentiation across diverse tissues. Dysregulated BMP signaling has been linked to cancers like colorectal and breast cancer, promoting invasion, tumor growth, and metastasis.

BMPR Signaling Pathway

Cell physiology and homeostasis rely on the integration of both extrinsic and intrinsic signals. Bone morphogenetic proteins (BMPs) represent a subset of cytokines within the TGF-β superfamily, pivotal in embryonic development, organogenesis, and overall bodily regulation. Upon interaction with BMPs, BMPRs undergo stimulation, forming a complex that initiates intracellular transduction cascades. Within the canonical pathway, BMPRs phosphorylate and activate the SMAD family of transcription factors, transmitting signals to the nucleus, as well as the PI3K/AKT and diverse MAPK pathways.

Fig.1 The schematic diagram of BMPR signaling pathways.^{1, 4}

Applications of Anti-BMPR Antibodies

BMPR signaling inhibition can be achieved through diverse pharmacological compounds. Therapeutic interventions can utilize neutralizing antibodies, which disrupt ligand-receptor interactions by targeting BMPRs, serving as therapeutic tools to impede BMPR signaling, thus playing a role in disorder treatment.

Fig.2 The inhibit factors targeting BMPRs.^{2, 4}

• Anti-BMPR Antibody in AML Therapy

Following cancer therapy, a considerable number of cases exhibit a resurgence of more aggressive tumors arising from immature cells. One instance is acute myeloid leukemia (AML), where the accumulation of immature cells precipitates relapse post-treatment. Intriguingly, the receptor BMPR1A transcript is upregulated in leukemic samples, with an augmented presentation of this receptor at the membrane in more cells. BMP4 exposure further enhances the high expression of BMPR1A, particularly in AML cells. Subsequent analysis has revealed that BMP4 modulates the expression of the survival factor ΔNp73 through its interaction with BMPR1A. Treatment of KG1A cells with BMP4, along with either an anti-BMPR1A blocking antibody or a chemical BMPR1 inhibitor, results in the abrogation of BMP4-induced ΔNp73 induction. These findings underscore the contribution of BMP pathway dysregulation to the elevated expression of the survival factor ΔNp73 in AML cells via the binding of BMP4 to BMPR1A-overexpressing leukemic cells. This study illuminates a novel signaling cascade instigated by alterations in the tumor environment, culminating in the acquisition of stem-cell characteristics.

Fig.3 Correlation of BMP-BMPR pathway activation with ΔNp73 overexpression in AML samples at diagnosis.^{3, 4}

Creative Biolabs presents a comprehensive selection of engineered anti-BMPR antibodies, meticulously produced through recombinant methodologies. Additionally, tailored customization services are available to tailor neutralizing antibodies directed against BMPR to specific specifications.

REFERENCES

1. Sánchez-de-Diego, Cristina, et al. "Interplay between BMPs and reactive oxygen species in cell signaling and pathology." Biomolecules 9.10 (2019): 534.
2. Gomez‐Puerto, Maria Catalina, et al. "Bone morphogenetic protein receptor signal transduction in human disease." The journal of pathology 247.1 (2019): 9-20.
3. Voeltzel, Thibault, et al. "A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome." Cell Death & Disease 9.10 (2018): 1011.
4. Distributed under Open Access license CC BY 4.0, without modification.